How to interpret a healthcare economic analysis

Current Opinion in Ophthalmology

Volumn 16, Issue 3, 2005, Pages 191-194

  Brown, Melissa M ^a,b,c,d   Brown, Gary C ^a,b,d  

^a CENTER FOR VALUE BASED MEDICINE   (United States)

^b Eye Research Institute   (United States)

^c WILLS EYE HOSPITAL   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Benefit; Economics; Healthcare; Ophthalmic; Value; Value based medicine

Indexed keywords

AMBLYOPIA; CATARACT; CATARACT EXTRACTION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; CRYOTHERAPY; DIABETIC RETINOPATHY; EVIDENCE BASED MEDICINE; EYE DISEASE; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; LASER COAGULATION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RETINA DETACHMENT; RETINA MACULA DEGENERATION; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; RETROLENTAL FIBROPLASIA; REVIEW; SUBRETINAL NEOVASCULARIZATION; VITRECTOMY;

COST-BENEFIT ANALYSIS; EYE DISEASES; HEALTH CARE COSTS; HUMANS; MODELS, ECONOMIC; QUALITY OF LIFE;

EID: 18844394808     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.icu.0000164166.55550.68     Document Type: Review

References (30)

1. Brown MM, Brown GC, Sharma S. Evidence-Based to Value-Based Medicine. Chicago, IL; AMA Press: 2005. A text that defines the field of value-based medicine and addresses healthcare economic analyses in greater detail.
2. Brown GC, Brown MM. Healthcare economic analyses. Evidence-based medicine and beyond. Retina 2004; 24:139-146. A review of healthcare economic analyses in the ophthalmic literature.
3. Briggs AH, O'Brien BJ. The death of cost-minimization analysis? Health Econ 2001; 10:179-184.
4. Cresswell PA, Allen ED, Tompkinson J, et al. Cost effectiveness of a single functioning treatment center for cataract surgery. J Cataract Refract Surg 1996; 22:940-946.
5. Tengs TO, Adams ME, Pliskin JP, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995; 15:369-390.
6. Gold MR, Patrick DL, Torrance GW, et al. Identifying and valuing outcomes. In Gold ME, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996:82-134.
7. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 2nd ed. Toronto: Oxford University Press; 2000:305.
8. Brown GC. Vision and quality of life. Trans Am Ophthalmol Soc 1999; 97: 473-512.
9. Brown MM, Brown GC, Sharma S, Landy J. Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration. Arch Ophthalmol 2002; 120:481-484.
10. Brown GC, Brown MM, Sharma S, Kistler J. Utility values associated with age-related macular degeneration. Arch Ophthalmol 2000; 118:47-51.
11. Brown MM, Brown GC, Sharma S, Shah G. Utility values and diabetic retinopathy. Am J Ophthalmol 1999; 128:324-330.
12. Brown MM, Brown GC, Sharma S, et al. Utility values associated with blindness in an adult population. Br J Ophthalmol 2001; 85:327-331.
13. Brown GC, Brown MM, Sharma S, et al. The reproducibility of ophthalmic utility values. Trans Am Ophthalmol Soc 2001; 99:71-76.
14. Hollands H, Lam M, Pater J, et al. Reliability of the time trade-off technique of utility assessment in patients with retinal disease. Can J Ophthalmol 2001; 36:202-209.
15. Sharma S, Brown GC, Brown MM, et al. Validity of the time trade-off and standard gamble methods of utility assessment in retinal patients. Br J Ophthalmol 2002; 86:493-496.
16. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization. Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992; 146: 473-481.
17. Heudebert GR, Centor RM, Klapow JC, et al. What is heartburn worth? A cost-utility analysis of management strategies. J Gen Intern Med 2000; 15: 175-182.
18. Brown GC, Brown MM, Sharma S, et al. Cost-effectiveness of therapy for threshold retinopathy of prematurity. Pediatrics 1999; 104:e47.
19. Sharma S, Hollands H, Brown GC, et al. The cost-effectiveness of early vitrectomy for the treatment of vitreous hemorrhage in diabetic retinopathy. Curr Opin Ophthalmol 2001; 12:230-234.
20. Busbee B, Brown MM, Brown GC, Sharma S. Incremental cost-effectiveness of initial cataract surgery. Ophthalmology 2002; 109:606-612.
21. Membreno J, Brown MM, Brown GC, et al. A cost-utility analysis of therapy for amblyopia. Ophthalmology 2002; 109:2265-2271.
22. Busbee B, Brown MM, Brown GC, Sharma S. A cost-utility analysis of cataract surgery in the second eye. Ophthalmology 2003; 110:2310-2317.
23. Sharma S, Brown GC, Brown MM, et al. The cost-effectiveness of grid laser photocoagulation for the treatment of diabetic macular edema: Results of a patient-based cost-utility analysis. Curr Opin Ophthalmol 2000; 11:175-179.
24. Brown GC, Brown MM, Sharma S, et al. Incremental cost-effectiveness of laser photocoagulation for choroidal neovascularization associated with histoplasmosis. Retina 2000; 20:331-337.
25. Brown GC, Brown MM, Sharma S. Incremental cost-effectiveness of laser therapy for subfoveal choroidal neovascularization. Ophthalmology 2000; 107:1374-1380.
26. Brown GC, Brown MM, Sharma S, et al. Incremental cost-effectiveness of therapeutic interventions for branch retinal vein occlusion. Ophthalmic Epidemiol 2002; 9:1-10.
27. Busbee B, Brown MM, Brown GC, Sharma S. A cost-utility analysis of laser photocoagulation for extrafoveal choroidal neovascularization. Retina 2003; 23:279-287.
28. Brown GC, Brown MM, Sharma S, Busbee B. A cost-utility analysis of interventions for proliferate vitreoretinopathy. Am J Ophthalmol 2002; 133:365-372.
29. Brown GC, Brown MM. Is prophylactic PRP in ischemic CRVO a good idea? Rev Ophthalmology 2000; 7:106,108,111.
30. Brown GC, Brown MM, Sharma S, et al. Value-based medicine and ophthalmology. An appraisal of cost-utility analyses. Trans Am Ophthalmol Soc 2004; 102:177-185. A comprehensive review of all of the ophthalmic cost-utility analyses in the literature to date.